# US 2023/0056712 A1 · Epstein-barr virus antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056712 A1
- Document ID: US20230056712A1
- Status: Published application
- Kind: A1
- Application number: 17/807,363
- Filed: 2022-06-16
- Published: 2023-02-23
- Earliest claimed: 2017-04-28
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: Javier Gordon OGEMBO; Lorraine Zvichapera MUTSVUNGUMA
- Web page: https://patentgrep.com/patent/US20230056712A1

## CPC

- C07K 16/085: Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more immunogenic peptides. Also disclosed are immunogenic peptides comprising fragments of gp350 amino acid sequence, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.

## Claims

### Claim 1

An antibody or an immunogenic fragment thereof that specifically binds to Epstein-Barr virus (EBV) glycoprotein (gp) 350 or glycoprotein 220.

### Claim 2 (depends on 1)

The antibody or the immunogenic fragment thereof of claim 1, wherein the antibody or the immunogenic fragment thereof specifically binds to a fragment of gp350 comprising residues 1-101, 102-201, or 402-501 of SEQ ID NO: 182.

### Claim 3 (depends on 2)

The antibody or the immunogenic fragment thereof of claim 2, comprising a heavy chain comprising a sequence at least 95% identical to SEQ ID NOs: 179 or 184.

### Claim 4 (depends on 3)

The antibody or the immunogenic fragment thereof of claim 3, comprising a light chain comprising a sequence at least 95% identical to SEQ ID NOs: 181 or 186.

### Claim 5 (depends on 4)

The antibody of claim 4, wherein the antibody is a monoclonal antibody.

### Claim 6 (depends on 4)

The antibody of claim 4, wherein the antibody is a chimeric antibody, a humanized antibody or a human antibody.

### Claim 7 (depends on 6)

The antibody of claim 6, wherein the antibody is humanized 72A1 or humanized E1D1.

### Claim 8

An immunogenic peptide comprising one or more fragments of gp350, wherein each fragment has an amino acid sequence identical to or sharing at least 60% similarity to residues 1-101, 102-201, or 402-501 of SEQ ID NO: 182.

### Claim 9 (depends on 8)

The immunogenic peptide of claim 8, further comprising a known immunogenic peptide such as keyhole limpet hemocyanin (KLH) peptide.

### Claim 10

An antibody-small molecule conjugate comprising:
an antibody or an immunogenic fragment thereof that specifically binds to a fragment of EBV gp350 or EBV gp220 comprising residues 1-101, 102-201, or 402-501 of SEQ ID NO: 182; and
a small molecule having an anti-proliferative activity against EBV-transformed cells,
wherein the small molecule is conjugated to the antibody.

### Claim 11 (depends on 10)

The conjugate of claim 10, wherein the antibody is a monoclonal antibody.

### Claim 12 (depends on 11)

The conjugate of claim 11, wherein the antibody is a chimeric antibody, a humanized antibody or a human antibody.

### Claim at position 13

13-16. (canceled)

### Claim 17 (depends on 4)

A pharmaceutical composition comprising the antibody or the immunogenic fragment thereof of claim 4.

### Claim 18 (depends on 4)

A method of neutralizing EBV infection comprising administering to a subject infected with EBV a therapeutically effective amount of the antibody or the immunogenic fragment thereof of claim 4.

### Claim 19 (depends on 4)

A method of preventing EBV infection comprising administering to a subject at an elevated risk of EBV infection a therapeutically effective amount of the antibody or the immunogenic fragment thereof of claim 4.

### Claim at position 17

20-24. (canceled)

### Claim 25 (depends on 4)

A method of immunizing or vaccinating a subject against EBV infection comprising administering to the subject a therapeutically effective amount of the antibody or the immunogenic fragment thereof of claim 4.

### Claim at position 19

26-29. (canceled)

### Claim 30 (depends on 8)

A pharmaceutical composition comprising the immunogenic peptide of claim 8.

### Claim 31 (depends on 8)

A method of neutralizing EBV infection comprising administering to a subject infected with EBV a therapeutically effective amount of the immunogenic peptide of claim 8.

### Claim 32 (depends on 8)

A method of preventing EBV infection comprising administering to a subject at an elevated risk of EBV infection a therapeutically effective amount of the immunogenic peptide of claim 8.

### Claim 33 (depends on 8)

A method of immunizing or vaccinating a subject against EBV infection comprising administering to the subject a therapeutically effective amount of the immunogenic peptide of claim 8.
